Drug Database
ER

erythropoietin beta (CinnaPoietin ß / CinnaPoietin)

✓ Approved

Cinnagen Co · EPOR · Recombinant Proteins

What is erythropoietin beta?

erythropoietin beta is a recombinant proteins developed by Cinnagen Co. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesCinnaPoietin ß, CinnaPoietin
CompanyCinnagen Co
Drug ClassRecombinant Proteins
Molecular TargetEPOR
RouteInjectable (Others), Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Cinnagen Co

Mechanism of Action

Molecular Targets

erythropoietin beta acts on 1 molecular target:

EPORerythropoietin receptor (EPO-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

erythropoietin beta is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

Related Research Articles

PubMedRenal failure2026-11-11

Longitudinal trajectory characteristics of the erythropoietin resistance index and their association with all-cause mortality in maintenance hemodialysis patients.

Yang Yun Y, He Wang W, Shi Junbo J, Wang Xiaoyun X et al.

Anemia is common in kidney failure, and most patients depend on erythropoiesis-stimulating agents (ESAs). We grouped maintenance hemodialysis (MHD) patients by how their erythropoietin resistance index (ERI) changed over time, and asked whether these patterns predicted death. We reviewed records of MHD patients treated at our center between 2021 and 2025. K-means clustering was applied to repeated ERI measurements to define trajectories. Logistic regression tested whether trajectory group, continuous ERI, and ERI quartile were related to all-cause mortality, the primary outcome. We also used spline models, subgroup and sensitivity analyses, and examined whether ERI improved prediction. A total of 150 patients were included, and 110 had enough repeated ERI data for trajectory analysis; 26 of them died (23.6%). Baseline ERI quartiles differed in dialysis vintage, dry weight, hemoglobin, and sex. In adjusted models, none of the ERI measures-continuous, quartile, or trajectory-predicted mortality. Dialysis vintage, sex, and hemoglobin were stronger predictors, and adding ERI barely changed discrimination. ERI varied widely between patients and tracked the severity of anemia and overall clinical state. It did not, however, show an independent association with death that we could detect. With a retrospective design and limited precision, our results are inconclusive about prognostic value rather than evidence that none exists.

PMID 43009750
Read full article →
PubMedJournal of education & teaching in emergency medicine2026-11-11

Ruptured Hemorrhagic Ovarian Cyst Mimicking Ruptured Ectopic Pregnancy in a Post-Transplant Patient: A Case Report.

Shah Saloni S, Lewis Kristin K, Hseuh Andy A

The incidence of syncope in the setting of ruptured ectopic pregnancy can vary widely; however, data specifically focusing on syncope as the primary presenting symptom without accompanying abdominal pain or vaginal bleeding are scarce.1,2 Our 23-year-old female patient, who is post-liver transplant and currently on immunosuppressive therapy, experienced syncope without significant pain or bleeding and presented to the ED with stable vital signs. Initial investigations revealed mild left lower quadrant tenderness, a serum beta-hCG of 95 mIU/mL, and moderate free pelvic fluid with a 28 mm left ovarian "cyst" on transvaginal ultrasound. These findings raised concerns for a ruptured ectopic pregnancy. Diagnostic laparoscopy, however, ultimately revealed a ruptured ovarian hemorrhagic cyst. Subsequent negative urine beta-hCG tests confirmed the initial serum beta-hCG as a false positive likely due to heterophile antibody interference, which is common in immunosuppressed patients. This case represents a rare mimic of a ruptured ectopic pregnancy which can occur in post-transplant patients and a nuanced interpretation of clinical workup. Syncope in reproductive-age women, ruptured ovarian cyst, ectopic pregnancy mimics, false-positive beta-hcg, heterophile antibody interference, emergency ultrasonography, diagnostic laparoscopy, immunosuppression and diagnostic challenges, atypical presentations of gynecologic emergencies.

PMID 43011960
Read full article →
PubMedBMC public health2026-11-11

Geographical disparities and temporal trends of end stage kidney disease incidence: a systematic review.

Tesfaw Lijalem M LM, Dalugoda Yohani Y, Tiong Mark K MK, Osborne Nicholas J NJ et al.

While individual studies address the geographical and temporal variations contributing to end-stage kidney disease (ESKD) incidence, there is a notable lack of comprehensive research consolidating these findings. This study systematically reviewed and analyzed original articles reporting the incidence of ESKD across different geographical locations and time over two decades worldwide. The study focused on individuals with ESKD, aged 18 and older, regardless of whether they received kidney replacement therapy. Original studies published between 01 Jan 2003 and 23 March 2026 focusing on ESKD incidence and reporting geographical variations and/or temporal trends were included. Literature screening and data extraction were performed using Covidence. Geographical variations in ESKD incidence were assessed across countries, major sub-divisions, and small areas, while temporal trends were evaluated both annually and seasonally. Among forty-one papers reviewed, 18 (43.9%) reported geographical variation, 17 (41.5%) reported temporal trends, and 6(14.6%) reported both. Of those examining geographical variations, 16.7% assessed ESKD incidence across countries, 33.3% across major sub-divisions, and 50.0% across small areas. ESKD incidence varies widely across regions, ranging from 100 per million population in Nepal to over 450 in Taiwan, with higher rates in high-income settings and notable within-country disparities in areas such as the southern United States, southern Taiwan, and parts of Japan. Incidence has increased over time, though some regions remain stable, with higher rates observed in winter than summer. Geographical variation in ESKD incidence was observed across countries, regions, and small areas, with notable increases over time. Factors impacting geographical variations include angiotensin converting enzyme inhibitor use, income, erythropoietin use, obesity, and paraquat exposure, while race, country of residence, diabetes type, hypertension, cardiovascular disease, and calendar year affect temporal variations. Both age and gender contribute to geographical and temporal variations.

PMID 43009887
Read full article →
PubMedAnalytical methods : advancing methods and applications2026-11-11

A unique liquid crystal-based biosensor for label-free detection of amyloid beta-42 peptide using gelsolin protein.

Tuncgovde Ebru E, Kemiklioglu Emine E, Kocabiyik Mine M, Erac Yasemin Y et al.

In this study, we report the development of a liquid crystal (LC)-based biosensor functionalized with gelsolin protein for the detection of Alzheimer's disease (AD)-related amyloid beta-42 (Aβ42). The gelsolin-modified glass substrate induced a robust homeotropic alignment of the LC molecules. Binding between gelsolin and Aβ42 disrupted this ordered orientation and produced a shift from a dark to a bright optical response under polarized optical microscopy (POM), enabling straightforward visual detection. The biosensor demonstrated a wide detection range of 1-1000 pg mL-1 and an exceptionally low detection limit of 1 pg mL-1 for Aβ42. In addition, apolipoprotein E4 (ApoE4), a major genetic risk factor for AD, was detected in the range of 0.1-30 nM. The interaction between Aβ42 and ApoE4 induced measurable changes in LC orientation, confirming the sensor's capability to transduce biomolecular interactions. Moreover, this LC-based biosensor was used for the detection of the Aβ42 peptide in cell culture samples. The obtained results demonstrate that with further optimization, the developed biosensor could pave the way for practical applications in real clinical samples.

PMID 43012735
Read full article →
PubMedCritical care medicine2026-11-11

Circulating Cell-Free Mitochondrial DNA, Delirium, and Long-Term Cognitive Impairment in Critically Ill Adults With Sepsis: A Prospective Cohort Study.

Onyemekwu Chukwudi A CA, Mart Matthew F MF, Prendergast Niall T NT, Toth Kelly M KM et al.

During sepsis, circulating cell-free mitochondrial DNA (ccf-mtDNA) is released and elevated due to cell injury, augments the immune response, and may contribute to organ dysfunction. Delirium is common and deleterious during sepsis, but little is known about the relationship between mitochondrial injury and delirium during sepsis. We sought therefore to examine associations between ccf-mtDNA and delirium and other clinical outcomes during sepsis. Multicenter, prospective cohort study. Medical and surgical ICUs in university and community hospitals in Nashville, TN. Four hundred eighty patients with sepsis plus shock and/or acute respiratory failure. None. We measured ccf-mtDNA in plasma collected on multiple days (study days 1, 3, and 5) during sepsis and assessed participants bid for delirium and coma using the validated Confusion Assessment Method for the ICU and Richmond Agitation-Sedation Scale. We then assessed survivors' cognitive function 3 and 12 months after hospital discharge using the Repeatable Battery for the Assessment of Neuropsychological Status. During sepsis, the adjusted odds of delirium were 7% lower for individuals at the 75th percentile of ccf-mtDNA compared with those at the 25th percentile (odds ratio [OR], 0.93; 95% CI, 0.86-0.99; p = 0.048). ccf-mtDNA was marginally associated with in-hospital mortality (hazard ratio, 1.09; 95% CI, 0.99-1.20; p = 0.08), but was not associated with coma (OR, 0.98; 95% CI, 0.90-1.05; p = 0.31) or 3-month (beta, 0.23; 95% CI, -1.58 to 2.05; p = 0.80) and 12-month (beta, -0.36; 95% CI, -2.13 to 1.42; p = 0.69) cognitive outcomes. In this multicenter, prospective cohort study, higher levels of ccf-mtDNA were associated with lower odds of delirium, a result that contradicted our hypothesis. This provocative finding should be interpreted cautiously until replicated and explained by future studies.

PMID 43012576
Read full article →
PubMedFrontiers in cardiovascular medicine2026-11-11

Treatment options for hypertrophic obstructive cardiomyopathy in the era of myosin inhibitors.

Nwuba Chukwunenyem C, Dungu Jason N JN

Hypertrophic obstructive cardiomyopathy (HOCM) is characterised by left ventricular outflow tract obstruction (LVOTO) caused by septal hypertrophy and its interaction with the mitral valve and systolic anterior motion. Symptoms include dyspnoea, angina, palpitations, syncope, fatigue and sudden cardiac death. This review provides a comprehensive overview and breakdown of current available treatment options, including traditional medical therapies and surgical septal reduction therapies in the era of new emerging pharmacologic options, including myosin inhibitors. Traditional pharmacotherapy includes non-vasodilating beta blockers, calcium-channel blockers and disopyramide. For persistent symptoms, surgical myectomy and alcohol septal ablation remain important septal reduction therapies, with treatment choice depending on anatomy, procedural risk and site-specific expertise. Myosin inhibitors, including mavacamten and aficamten, offer a targeted approach to addressing the hypercontractility characteristic of hypertrophic obstructive cardiomyopathy, by directly modulating sarcomeric function. These agents may move earlier in the treatment pathway for selected patients with HOCM, although longer-term data, access, monitoring burden and cost-effectiveness remain important considerations.

PMID 43011260
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about erythropoietin beta